Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
BrainsWay logo — Global leader in advanced noninvasive neurostimulation treat...

BrainsWay

Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.

Founded 2003 United States Burlington, United States 132 employees Post Ipo Equity Total: $87.00M Biotechnology, Health Care

General Information

Company Name BrainsWay
Founded Year 2003
Location United States Burlington, United States +3
Employees 132
Industries Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when BrainsWay moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About BrainsWay

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company, founded in 2003, is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. With offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. At 23 February 2021, the company secured a $45.20M Post-IPO Equity investment. For more information, visit www.brainsway.com.

Taxonomy: Neurostimulation, Deep TMS, Noninvasive treatments, Mental health disorders, FDA-cleared indications, Clinical trials, Brain disorder treatment, Medical devices, Neuromodulation, Neurology, Depression treatment, Obsessive-compulsive disorder treatment, Smoking addiction treatment, Global leader, Patient wellbeing

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 23 Feb 2021
Post-IPO Equity •••••• 3
Investor
•••• •••• 		11 Dec 2017
Post-IPO Equity •••••• - 01 Jan 2015
Post-IPO Equity •••••• 1 •••• •••• 11 Mar 2014

BrainsWay Alternatives & Competitors

BrainsWay vs
Cambridge Biotherapies
Cambridge Biotherapies United States

Revolutionary Mental Health Care: Psychedelic Therapy, Ketamine, TMS, Medication Management

10 employees
Health Care, Health and Wellness
Compare BrainsWay vs Cambridge Biotherapies
BrainsWay vs
TMS Clinics Of Canada
TMS Clinics Of Canada Canada

Using breakthrough technology, professionalism, and compassion to better lives. TMS Of Canada, Love...

3 employees
Health Care, Health and Wellness
BrainsWay vs
Magnolia Creek Center for Eating Disorders
Magnolia Creek Center for Eating Disorders United States

Eating Disorder Treatment Center for Adult Women near Birmingham, Alabama.

41 employees
Health Care
Also compare with: BrainsWay vs Serenity Healthcare Serenity Healthcare BrainsWay vs Pacific Mind Health Pacific Mind Health

FAQ About BrainsWay

Global leader in advanced noninvasive neurostimulation treatments for mental health disorders.
BrainsWay was founded in 2003.
BrainsWay is headquartered in Burlington, United States.
BrainsWay operates in the following industries: Biotechnology, Health Care.
BrainsWay has approximately 132 employees.
BrainsWay has completed 4 funding rounds, raising a total of $87.00M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to BrainsWay include Cambridge Biotherapies, TMS Clinics Of Canada, Magnolia Creek Center for Eating Disorders, Serenity Healthcare, Pacific Mind Health. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BrainsWay and Cambridge Biotherapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors BrainsWay and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes